Skip to main content
. 2021 May 28;12:582447. doi: 10.3389/fphar.2021.582447

TABLE 4.

Sensitivity analysis.

Indicators Trials SM OR (95%CI) I2 Excluded trials (Reference number) Trials SM OR (95%CI) I 2
Table 4A. Sensitivity analysis by excluding the poor trials
Objective response rate 63 FEM 1.82 [1.62, 2.04] 0% Poor* Zou et al. (2006), Feng et al. (2008), Zhao et al. (2008), Lv et al. (2009), Song et al. (2009), Zhang. (2009), Hou and Zhang. (2010), Li et al. (2010), Shi et al. (2010), Ding et al. (2011), He et al. (2011), Lu et al. (2011), Fu. (2012), Sun et al. (2012), Xu et al. (2012), Ju et al. (2013), Lai. (2013), Xu et al. (2013), Li et al. (2014), Li and Yang. (2014), Zhao et al. (2015), Zhang. (2016b), Fang. (2016), Li. (2016), Li et al. (2016), Huang et al. (2017), Ma. (2017), Su. (2017), Zhang et al. (2017), Liu et al. (2019), Zhao and Li. (2019), Xu. (2020), Xu and Li. (2020) 30 FEM 1.80 [1.53, 2.13] 0%
Disease control rate 61 FEM 2.29 [1.97, 2.67] 0% Poor* Zou et al. (2006), Feng et al. (2008), Lv et al. (2009), Song et al. (2009), Zhang. (2009), Hou and Zhang. (2010), Li et al. (2010), Shi et al. (2010), He et al. (2011), Lu et al. (2011), Fu. (2012), Sun et al. (2012), Xu et al. (2012), Ju et al. (2013), Lai. (2013), Xu et al. (2013), Li et al. (2014), Li and Yang. (2014), Zhang. (2016a), Zhang. (2016b), Fang. (2016), Li. (2016), Li et al. (2016), Huang et al. (2017), Ma. (2017), Su. (2017), Zhang. (2018), Liu et al. (2019), Zhao and Li. (2019), Xu. (2020), Xu and Li. (2020) 30 FEM 2.20 [1.78, 2.71] 0%
Quality of life 31 FEM 3.03 [2.55, 3.60] 0% Poor*Zou et al. (2006), Feng et al. (2008), Zhao et al. (2008), Lv et al. (2009), Song et al. (2009), Zhang. (2009), Hou and Zhang. (2010), Li et al. (2010), Shi et al. (2010), He et al. (2011), Sun et al. (2012), Ju et al. (2013), Lai. (2013), Xu et al. (2013), Liu and Zhang. (2014), Zhang. (2016a), Zhang. (2016b), Li. (2016) 13 FEM 3.27 [2.54, 4.21] 0%
Myelosuppression 17 FEM 0.36 [0.28, 0.47] 31% Poor* Zou et al. (2006), Lv et al. (2009), Song et al. (2009), Li et al. (2010), Shi et al. (2010), He et al. (2011), Xu et al. (2012), Cai et al. (2013), Ju et al. (2013), Lai. (2013), Li et al. (2014), Su. (2017) 5 REM 0.37 [0.16, 0.85] 69%
Neutropenia 40 FEM 0.0.41 [0.35, 0.49] 0% Poor* Feng et al. (2008), Zhang. (2009), Hou and Zhang. (2010), Lu et al. (2011), Fu. (2012), Sun et al. (2012), Xu et al. (2012), Xu et al. (2013), Li and Yang. (2014), Zhang. (2016a), Fang. (2016), Li. (2016), Li et al. (2016), Huang et al. (2017), Ma. (2017), Su. (2017), Zhang et al. (2017), Zhang. (2018), Xu. (2020) 21 FEM 0.44 [0.35, 0.54] 0%
Thrombocytopenia 28 FEM 0.48 [0.39, 0.59] 0% Poor* Feng et al. (2008), Zhang. (2009), Hou and Zhang. (2010), Xu et al. (2012), Xu et al. (2013), Li and Yang. (2014), Fang. (2016), Li et al. (2016), Huang et al. (2017), Su. (2017), Xu. (2020) 17 FEM 0.52 [0.40, 0.67] 4%
Anemia 11 FEM 0.59 [0.43, 0.80] 5% Poor* Li and Yang. (2014), Li. (2016), Ma. (2017), Zhang. (2018) 7 FEM 0.71 [0.48, 1.04] 0%
Gastrointestinal toxicity 49 FEM 0.45 [0.39, 0.51] 0% Poor* Zou et al. (2006), Feng et al. (2008), Lv et al. (2009), Song et al. (2009), Zhang. (2009), Hou and Zhang. (2010), Li et al. (2010), Liu et al. (2010), Shi et al. (2010), He et al. (2011), Lu et al. (2011), Sun et al. (2012), Xu et al. (2012), Cai et al. (2013), Ju et al. (2013), Lai. (2013), Xu et al. (2013), Li et al. (2014), Zhang. (2016a), Fang. (2016), Li. (2016), Li et al. (2016), Su. (2017), Zhang et al. (2017), Zhang. (2018) 24 FEM 0.44 [0.36, 0.53] 0%
Liver toxicity 29 FEM 0.58 [0.47, 0.72] 0% Poor* Hou and Zhang. (2010), Sun et al. (2012), Li et al. (2014), Zhang. (2016a), Huang et al. (2017), Ma. (2017), Zhang et al. (2017) 22 FEM 0.57 [0.46, 0.72] 0%
Renal toxicity 24 FEM 0.62 [0.48, 0.79] 0% Poor* Sun et al. (2012), Li et al. (2014), Huang et al. (2017), Ma. (2017) 20 FEM 0.60 [0.46, 0.79] 0%
Alopecia 3 REM 0.27 [0.05, 1.37] 70% Poor* Song et al. (2009) 2 FEM 0.12 [0.04, 0.34] 0%
Neurotoxicity 5 FEM 0.63 [0.35, 1.12] 0% Poor* Song et al. (2009) 4 FEM 0.58 [0.31, 1.09] No
Table 4B. Sensitivity analysis by excluding the over- or under-estimated trials
 Objective response rate 63 FEM 1.82 [1.62, 2.04] 0% Over* Zou et al. (2006), Yang et al. (2008), Lv et al. (2009), Hong et al. (2010), Wen. (2014), Ning et al. (2015), Zhu. (2015), Zhang. (2016b), Li et al. (2016), Su. (2017), Wu and Chen. (2017), Zhang et al. (2017), Su and Zhang. (2019), Zhao and Li. (2019), Chen. (. (2020), Geng et al. (2020), Xu. (2020) 46 FEM 1.47 [1.28, 1.69] 0%
 Disease control rate 61 FEM 2.29 [1.97, 2.67] 0% Over* Hong et al. (2010), Pei. (2012), Wang and Peng. (2012), Wen. (2014), Zhao et al. (2015), Zhang. (2016b), Fang. (2016), Li et al. (2016), Huang et al. (2017), Ma. (2017), Su. (2017), Zhou. (2018), Liu et al. (2019), Chen. (2020), Geng et al. (2020), Tan et al. (2020), Xu. (2020), Xu and Li. (2020) 43 FEM 1.78 [1.47, 2.16] 0%
 Quality of life 31 FEM 3.03 [2.55, 3.60] 0% Over* Zou et al. (2006), Feng et al. (2008), Yang et al. (2008), Zhao et al. (2008), Lv et al. (2009), Song et al. (2009), Wen et al. (2009), Hong et al. (2010), Hou and Zhang. (2010), Li et al. (2010), Shi et al. (2010), Fan et al. (2011), He et al. (2011), Jiang et al. (2011), Wang and Peng. (2012), Ju et al. (2013), Wu et al. (2017b), Su and Zhang. (2019) 13 FEM 2.07 [1.56, 2.73] 0%
 Myelosuppression 17 FEM 0.36 [0.28, 0.47] 31% Under*Lv et al. (2009), Li et al. (2010), Liu et al. (2010), Shi et al. (2010), He et al. (2011), Xu et al. (2012), Ju et al. (2013), Zhou. (2018), Su and Zhang. (2019) 8 FEM 0.61 [0.43, 0.86] 0%
 Neutropenia 40 FEM 0.0.41 [0.35, 0.49] 0% Under* Wen et al. (2009), Zhang. (2009), Hong et al. (2010), Hou and Zhang. (2010), Lu et al. (2011), Fu. (2012), Sun et al. (2012), Xu et al. (2012), Cheng et al. (2014), Liu and Zhao. (2014), Li. (2015), Zhang. (2015), Zhu. (2015), Fang. (2016), Li. (2016), Wu and Chen. (2017), Zhang. (2018), Chen. (2020), Guo. (2020) 21 FEM 0.56 [0.44, 0.71] 0%
 Thrombocytopenia 28 FEM 0.48 [0.39, 0.59] 0% Under* Hong et al. (2010), Wang and Peng. (2012), Xu et al. (2012), Zhu. (2015), Guo. (2020), Tan et al. (. (2020) 22 FEM 0.57 [0.45, 0.74] 0%
 Anemia 11 FEM 0.59 [0.43, 0.80] 5% Under* Li. (2016), Wu and Chen. (2017) 9 FEM 0.68 [0.48, 0.96] 0%
 Gastrointestinal toxicity 49 FEM 0.45 [0.39, 0.51] 0% Under* Lv et al. (2009), Wen et al. (2009), Zhang. (2009), Hong et al. (2010), Hou and Zhang. (2010), Shi et al. (2010), Lu et al. (2011), Xu et al. (2012), Wen. (2014), Zhu. (. (2015), Fang. (2016), Li. (2016), Li et al. (2016), Ma and Jiang. (2016), Wu et al. (2017b), Wu and Chen. (2017), Zhang et al. (2017), Zhang. (2018), Su and Zhang. (. (2019), Guo. (2020) 29 FEM 0.61 [0.51, 0.75] 0%
 Liver toxicity 29 FEM 0.58 [0.47, 0.72] 0% Under* Wu et al. (2017b), Wu and Chen. (2017), Su and Zhang. (2019) 26 FEM 0.68 [0.54, 0.86] 0%
 Renal toxicity 24 FEM 0.62 [0.48, 0.79] 0% Under* Wu et al. (2017b) 23 FEM 0.67 [0.51, 0.87] 0%
 Alopecia 3 REM 0.27 [0.05, 1.37] 70% Under* Wang. (2009), Liu et al. (2010) 1 No 1.38 [0.28, 6.80] No
 PBL Trials SM SMD (95% CI) I2 Excluded trials (Reference number) Trials SM SMD (95% CI) I2
Table 4C. Sensitivity analysis by excluding the poor trials
 CD3+ T cell 14 REM 1.12 [0.69, 1.55] 92% Poor* Li et al. (2016), Huang et al. (2017), Ma. (2017), Liu et al. (2019), Zhao and Li. (2019), Xu. (2020) 8 REM 0.86 [0.29, 1.43] 93%
 CD3+ CD4+ T cell 15 REM 1.34 [0.99, 1.68] 88% Poor* Li et al. (2016), Huang et al. (2017), Ma. (2017), Su. (2017), Liu et al. (2019), Zhao and Li. (2019), Xu. (2020) 8 REM 1.40 [0.81, 1.98] 92%
 CD4+/CD8+ T cell ratios 11 REM 0.96 [0.57, 1.35] 88% Poor* Li et al. (2016), Huang et al. (2017), Ma. (2017), Liu et al. (2019), Zhao and Li. (2019) 7 REM 0.93 [0.47, 1.38] 86%
 Natural killer cell 3 REM 0.96 [0.22, 1.71] 86% Poor* Li et al. (2016) 2 REM 1.27 [0.32, 2.21] 84%
Table 4D. Sensitivity analysis by excluding the over- or under-estimated trials
 CD3+ T cell 14 REM 1.12 [0.69, 1.55] 92% Over* Jiang et al. (2011), Han et al. (2015), Zhao et al. (2015), Li et al. (2016), Huang et al. (2017), Ma. (2017), Liu et al. (2019), Xu. (2020) Under* Zhang. (2014) 5 FEM 0.46 [0.28, 0.63] 0%
 CD3+ CD4+ T cell 15 REM 1.34 [0.99, 1.68] 88% Over* Jiang et al. (2011), Han et al. (2015), Zhao et al. (2015), Li et al. (2016), Ma. (2017), Su. (2017), Lv et al. (2018),under* Wu et al. (2017b) 7 FEM 0.97 [0.80, 1.13] 26%
 CD4+/CD8+ T cell ratios 11 REM 0.96 [0.57, 1.35] 88% Over* Jiang et al. (2011), Han et al. (2015), Wu et al. (2017b), Liu et al. (2019) 7 FEM 0.48 [0.32, 0.65] 0%
 Natural killer cell 3 REM 0.96 [0.22, 1.71] 86% Over* Jiang et al. (2011) 2 FEM 0.56 [0.25, 0.88] 37%

Note: PBL: Peripheral blood lymphocyte; SM: statistical method; FEM: fixed-effects model; OR: odds ratio; SMD: standardized mean difference; CI: confidence interval; Poor trial (Poor*) that had at least one domain being considered as high risk of bias; and Over* or Under*: over or underestimated trial which the result was significant difference and beneficial to Aidi injection use.